Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy ...

Kidney complement-related gene expression may be poorly reflected by routine blood tests and biopsy staining, and lower alternative-pathway expression might be associated with lower risks of kidney ...

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved ...

Historically, clinical operations have focused on finding and correcting errors after they occur. Source data verification, monitoring visits, reconciliation activities, protocol deviation reviews and ...

Akebia Therapeutics, Inc. ( AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA ...

Biogen published results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology ...

Auri, the Auracast-based assistive listening system, makes it easy for anyone to connect to clear audio in worship facilities ...

Discover how architectural composite fabrics are being used to shape building envelopes, control daylight and acoustics, and ...

Breathizen is a U.S.-manufactured liquid dietary supplement containing a combination of botanical extracts and naturally ...

Nepal's government health system operates on local as well as provincial and federal government levels, with local facilities focusing on basic health services, while provincial and federal hospitals ...